Main Menu

This technology relates to the generation and use of an antibody that recognizes the S1459 phosphorylated site of the GRIN2A gene, which encodes the GluN2A subunit of the NMDA receptor. This gene is widely accepted as an epilepsy-causative gene and has been implicated in autism spectrum disorder (ASD). The S1459 phosphorylation site was selected based on an identified mutation in an epilepsy patient. This antibody can be used to specifically visualize the localization of the phosphorylated version of the GRIN2A protein product in the brain.

This technology includes the generation and use of an antibody that can detect endogenous Neuroligin 4Y, NLGN4Y, a cell adhesion molecule on the X-chromosome. NLGN4Y is part of an X-Y pair with NLGN4X, which has been implicated with autism spectrum disorder (ASD) and intellectual disability. ASD has a sex bias etiology that is not well understood, affecting four times as many males as females. Previous work has revealed a potential pathogenic mechanism for male-bias based on mutations in NLGN4X and NLGN4Y. The use of the NLGN4Y antibody could be used to study potential mechanisms.

This technology includes the creation and use of a mouse anti-Atlastin-1 monoclonal antibody (3194, IgG1). Mutations in Atlastin-1 are commonly found in hereditary spastic paraplegia, SPG3A. In addition, this protein is conserved in all eukaryotes, and it mediates fusion of endoplasmic reticulum tubules in cells, giving it its characteristic polygonal appearance. Thus, this protein is of interest to both those interested in disease pathogenesis and those studying basic cell biology.

This invention includes the generation and use of a polyclonal antibody for synapse-associated protein 102 (SAP102) and a polyclonal antibody that binds to mGluR7 when phosphorylated at Serine 862. Peptides of the sites were generated and injected into rabbits to create an immune response. Serum was collected from the rabbits that was then affinity purified. The specificity of the resulting polyclonal antibodies was then determined using biochemical techniques.

This invention includes the generation and use of polyclonal antibodies that specifically recognize the glutamate receptor 1 protein that has been phosphorylated at Serine 567 (GluA1 pS567). Glutamate receptors are ligand-gated ion channels and are the predominant excitatory neurotransmitter receptor type in humans. A peptide sequence on the gene was selected surrounding the phosphorylation site. This peptide was then generated and injected into rabbits to create an immune response. Serum was then collected from the rabbit and the antibodies were affinity purified.

This invention includes the generation and use of monoclonal antibodies that specifically recognize either arginine vasopressin (AVP) or oxytocin (OT) when bound to neurophysins. The neurophysins (NPs) are a family of proteins that bind to hormones as they are released from the hypothalamus and make their way to the pituitary gland. Monoclonal antibodies were generated that specifically recognize vasopressin bound to a neurophysin (NP-AVP) or oxytocin bound to a neurophysin (NP-OT). Seven monoclonal antibodies were characterized.

This technology includes the creation and use of a polyclonal antibody for Neuroligin-4, NLGN4, that was created by injecting a peptide surrounding the pT707 phosphorylation site into rabbits and affinity purifying the resulting serum. Neuroligin-4 is a member of the neuroligin family of cell adhesion proteins. This family has been shown to play a role in the maturation and function of the neuronal synapse and has been implicated in patients with autism and intellectual disability.

This technology includes a therapeutic approach to prevent secondary edema after cerebrovascular hemorrhage. Using an animal model, we found that edema is triggered by massive extravasation of myelomonocytic cells from the blood into the brain in response to hemorrhaging vessels. Administration of anti-LFA1 and anti-VLA4 antibodies resulted in an inhibition of extravasation of the myelomonocytic cells. This single dose treatment prevented secondary edema and markedly improved functional outcomes if administered within the first six hours following cerebrovascular hemorrhage.

This technology includes the development and use of the VA-17 antibody that detects both amidated and extended forms of Oxytocin in radioimmunoassay. This antibody can be used for in vitro work, including RIA assays, to detect both forms of Oxytocin: amidated and extended.

This technology includes the generation and use of novel rabbit polyclonal antibodies against a GST-tagged portion of the human protein mitofusin 1 (amino acids 667-741).